CN104906084A - Application of artemisinin and derivatives thereof in preparation of ophthalmic vascular disease prevention and treatment medicines, and medicinal composition - Google Patents
Application of artemisinin and derivatives thereof in preparation of ophthalmic vascular disease prevention and treatment medicines, and medicinal composition Download PDFInfo
- Publication number
- CN104906084A CN104906084A CN201410088930.7A CN201410088930A CN104906084A CN 104906084 A CN104906084 A CN 104906084A CN 201410088930 A CN201410088930 A CN 201410088930A CN 104906084 A CN104906084 A CN 104906084A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- injection
- arteannuin
- new vessels
- retinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an application of artemisinin and derivatives thereof in the preparation of medicines for inhibiting proliferation of ophthalmic vascular endothelial cells or preventing and treating ocular vascular system effusion, oedema and newborn blood vessel formation propagation associated diseases, and a medicinal composition containing the artemisinin and the derivatives thereof. The artemisinin and the derivatives thereof can be used for preventing and treating ocular vascularity associated diseases, such as age-related macular degeneration, diabetic retinopathy, central retinal vein occlusion and branch retinal artery occlusion.
Description
Technical field
The present invention relates to ophthalmology vascular conditions field, particularly relate to the application in the vascular-associated disease medicament of preparation control ophthalmology of arteannuin and derivant thereof and pharmaceutical composition.
Background technology
Arteannuin (artemisinin, Q) arteannuin, Hemerocallis citrina Baroni element, arteannuin is had another name called, it is the sesquiterpene lactones medicine having peroxy-radical extracted from plant ginghao, its common derivant has: dihydroarteannuin (Dihydroartemisinin, DI), artesunate (Artesunate, ART), Artemether (artemether, J), arteether (Arteether), artemisia ketone (Artemisone) etc.Owing to there is peroxide bridge in its molecular structure, the free iron produced after hemoglobin is decomposed mediated, produce free radical, arteannuin and derivant thereof are mainly used in killing plasmodium in the prior art, be mainly used in the treatment of all kinds malaria at present, especially resisting the pernicious and pernicious malaria of chloroquine has good therapeutic effect.
At present, ocular angiogenesis oozes out, edema, the pathological processes such as new vessels formation and propagation are the main causes of the many diseases causing blindnesses of ophthalmology, wherein especially serious with the harm of retina choroid vascular conditions, macular degeneration related (the age-related macular degeneration of topmost disease has age, AMD), Diabetic retinopathy (diabetic retinopathy, DR), central retinal vein occlusion (central retinal vein occlusion, CRVO), branch retinal vein occlusion remaining (branch retinal vein occlusion, BRVO), retinopathy of prematurity (retinopathy of prematurity, and meniscocyte's retinal diseases (sickle cell retinopathy) etc. ROP), wherein AMD and DR is the Etiological of adult's blinding.
And the main policies for the treatment of retina choroid new vessels has: intravitreal, laser and optical dynamic therapy, and gene therapy etc.The medicine of current clinical practice has: Lucentis (Lucentis), bevacizumab (Avastin), Macugen (pegaptanib), and carry out Trap Eye, KH902 and Sima-027 of clinical trial, wherein based on injection in Lucentis, bevacizumab vitreous chamber.Lucentis, bevacizumab are the medicines that current Ying Yu is the widest, evidence-based medical is comparatively perfect, serve and well stop visual loss, improve patient's vision in clinical treatment, suppress the effect of new vessels.But along with applying more and more widely, itself Problems existing also manifests gradually:
1, Lucentis is as the antibody fragment of molecular weight 48kDa, and reaching vitreous chamber peak concentration time after intravitreal is 1 day, and the removing half-life is approximately 3 days, keeps the bioactive time to be approximately one month.Therefore First Year mean injection 6.9 times.Injection may produce multiple complications repeatedly: the rising of detachment of retina, retinal hole, intraocular pressure, cataract etc., even endophthalmitis;
2, still there are 10 ~ 20% patient treatments invalid, and have some patients to occur drug resistance after repeatedly treating, therapeutic effect declines;
3, expensive, limit its application to a certain extent.
Laser and optical dynamic therapy are also suppress new vessels to be formed, and promote effective therapeutic modality that new vessels disappears, and can delay patient's visual deterioration.But have trauma care mode as one, laser therapy causes irreversible infringement to circle-of-sight visibility, and some patients can recur.
Summary of the invention
Based on this, an object of the present invention is to provide a kind of arteannuin and the application of derivant in preparation control ophthalmology vascular conditions medicine thereof.
The concrete technical scheme solved the problems of the technologies described above is as follows:
Arteannuin and derivant thereof suppress ocular angiogenesis endothelial cell proliferation in preparation or prevent and treat the application in the medicine of the relevant disease that ocular angiogenesis system is oozed out, edema, new vessels are formed, breed.
Wherein in some embodiments, described control ocular angiogenesis system is oozed out, edema, new vessels is formed, the relevant disease of propagation is age-related macular degeneration (age-related macular degeneration, AMD), Diabetic retinopathy (diabetic retinopathy, DR), central retinal vein occlusion (central retinal vein occlusion, CRVO), branch retinal vein occlusion remaining (branch retinal vein occlusion, BRVO), retinopathy of prematurity (retinopathy of prematurity, ROP), Coats disease (retinal angiotelectasis disease), macular edema (Macular edema), periphlebitis of retina (young recurrent retina vitreous hemorrhage, Eales is sick), polypoidal choroidal vasculopathy in Chinese patients (polypoidal choroidal vasculopathy, PCV), neovascular glaucoma (neovascular glaucoma, NVG), cornea rebirth blood vessel (corneal neovascularization), iris neovascularization (iris neovascularization), choroidal neovascularization (choroidal neovascularization), retinal neovascularization (retinal neovascularization), eye and Orbital fat (orbital tumor), inflammatory pseudotumor (inflammatory pseudotumor), thyroid-associated ophthalmopathy (thyroid-associated ophthalmopathy), thyroid related immune Orbital diseases (Thyroid related immune orbitopathy), features of central exudative chorioretinopathy (central exudative chorioretinopathy), the new vessels that high myopia causes and hemorrhage, uveitis (uveitis), proliferative vitreoretinopathy (PVR, Proliferative vitreoretinopathy) and traumatic proliferative vitreoretinopathy (PVR), retinal angiomatous (retinal hemangioma) and meniscocyte's retinal diseases (sickle cell retinopathy).
Wherein in some embodiments, it is retina choroid neovascular diseases that described new vessels forms relevant disease.
Another object of the present invention is to provide a kind of for suppressing ocular angiogenesis endothelial cell proliferation or control ocular angiogenesis system is oozed out, edema, new vessels are formed, the pharmaceutical composition of the relevant disease of propagation, the effective ingredient of described pharmaceutical composition is arteannuin and derivant thereof.
Wherein in some embodiments, the medicine carrying mode of described pharmaceutical composition is: arteannuin and derivant thereof to be dissolved on 0.9% sodium chloride solution or medicine in acceptable dissolution solubilizing agent; Or adopt slow release method arteannuin and derivant thereof to be made nanoparticle (nanoparticles), micelle (micelles), nanometer microtubule (nanotubes) or dendritic macromole (dendrimers).
Wherein in some embodiments, described dissolution solubilizing agent is: at least one in sodium bicarbonate solution, dimethyl sulfoxide, ethanol, lecithin, lactic acid, glycerol, stearic acid polyethylene, polyvinyl alcohol, soybean phospholipid or poloxamer.
Wherein in some embodiments, the dosage form of described pharmaceutical composition is eye drop or injection.
Wherein in some embodiments, the route of administration of described injection is: ball is injected outward, implanted treatment or intraocular injection; Described ball is injected as subconjunctival injection, the injection of ball week, retrobulbar injection or sieve plate surrounding injection outward; Described intraocular injection is anterior chamber and intravitreal.
Wherein in some embodiments, described eye drop carries out administration by conjunctival sac.
Above-mentioned artemisinin derivative is dihydroarteannuin, artesunate, Artemether, arteether or artemisia ketone.
The application in preparation treatment ophthalmology vascular conditions medicine of arteannuin of the present invention and derivant thereof has the following advantages and beneficial effect: the present invention through the great many of experiments of inventor and research, draw arteannuin and derivant thereof suppress ocular angiogenesis endothelial cell proliferation or control ocular angiogenesis system is oozed out, edema, new vessels are formed, propagation diseases related in there is significant effect; And its persistent, not only reduce intraocular injection number of times, decrease the generation of complication.
Accompanying drawing explanation
Fig. 1 is arteannuin in embodiment 2, dihydroarteannuin, artesunate, Artemether induction HUVEC apoptosis result figure;
Fig. 2 is arteannuin in embodiment 2, dihydroarteannuin, artesunate, Artemether induction RF/6A apoptosis result figure;
Fig. 3 is the Comparative result figure of each group fundus photography in vivo test in embodiment 2;
Fig. 4 is the Comparative result figure of each group fundus fluorescein angiography in vivo test in embodiment 2.
Detailed description of the invention
Below with reference to specific embodiment, the present invention will be further described.
Embodiment 1
The application of artesunate in preparation treatment retina choroid new vessels generating medicine, specifically comprises following content:
(1) dosing: artesunate and 0.05% sodium bicarbonate solution are made into 0.1-6mg/ml gradient solution;
(2) dosage: 0.1-0.5ml;
(3) operating procedure:
A, field of operation are sterilized: with 10% povidone iodine sterilization eyelid and periocualr skin, after 3 0.5% povidone iodine are placed on conjunctival sac a few minutes, rinse conjunctival sac by tobramycin solution, with antibiotic eye drop prevention bitot's patches and wearing and tearing.
B, local anesthesia: 3 ~ 4 Ai Erkaiyin eye drop instillation conjunctival sacs are carried out local anesthesia.
C, intravitreal: injection site should be positioned at 3.5-4 millimeter after limbus of corneae, syringe uses No. 30 syringe needles to be tilted through episclera, then vertically thrusts, thrusts the degree of depth between 5-7mm, needle point is made to be positioned at middle vitreous body, by medicine implantation glass body cavity gently; During duplicate injection, each mobile hour.
Embodiment 2
(1) in vitro tests
One, experiment purpose
Pass through experiment in vitro, analyze arteannuin (Q) and derivant (artesunate (ART), dihydroarteannuin (DI) and Artemether (the J)) impact on HUVEC and RF/6A thereof, namely arteannuin and derivant suppression HUVEC and RF/6A propagation thereof is analyzed, the situation of induction HUVEC and RF/6A apoptosis, to screen the most effective artemisinin derivative monomer further, calculate IC50, to find appropriate effect concentration.
Two, experimental technique
(1) extract Human umbilical vein endothelial cells (human umbilical vein endothelial cell, HUVEC) carry out original cuiture, 2-4 for cell for.
(2) arteannuin and the experiment of derivatives monomer induction HUVEC apoptosis thereof
Experimental subject: HUVEC, Rhesus Macacus retina choroid vascular endothelial cell (RF/6A);
Experimental technique is as follows, and apoptosis test (MTT), repeats 3 times.
Specific experiment step:
1, collect logarithmic (log) phase cell, adjustment concentration of cell suspension to 50000/ml, every hole adds 100ul cell suspension (5000, every hole cell).(the aseptic PBS of edge hole fills).
2, in 5%CO2, hatch for 37 DEG C, merge (96 hole flat underside), add the medicine of Concentraton gradient, every hole 100ul to Growth of Cells to 80%, each concentration establishes 5 multiple holes.
3,5%CO2, hatches 24 hours for 37 DEG C, observes under inverted microscope.
4, treatment fluid in exhaustion hole, every hole adds 200 μ lMTT solution (0.5mg/ml), continues to cultivate 4h.
5, stop cultivating, carefully suck MTT solution in hole.
6, every hole adds 150 μ l dimethyl sulfoxide (DMSO), puts low-speed oscillation 10min on shaking table, crystal is fully dissolved.The light absorption value in each hole is measured at enzyme-linked immunosorbent assay instrument OD490nm place.
Three, experimental result
Artesunate (Artesunate, ART), dihydroarteannuin (Dihydroartemisinin, DI), arteannuin (artemisinin) and Artemether (artemether, J) induce HUVEC and RF/6A apoptosis effect, and result is see Fig. 1 and Fig. 2.
As can be seen from Figure 1: artesunate (ART) IC50:28.7 ± 2.53 μ g/ml, dihydroarteannuin (DI) IC50:2.1 ± 0.37 μ g/ml, artesunate and dihydroarteannuin can obviously suppress HUVEC to breed when this tests concentration used, induction HUVEC apoptosis, wherein dihydroarteannuin suppresses HUVEC proliferation function to be better than artesunate, and arteannuin and Artemether suppress HUVEC proliferation function when this tests concentration used without obvious.
The results showed: the effect of HUVEC apoptosis can appear inducing in arteannuin when the 500 above concentration of μ g/ml, and Artemether need just have apoptosis-induced effect higher than the oil solution of 1mg/ml.
As can be seen from Figure 2: arteannuin and derivant thereof, in induction RF/6A apoptosis, show the trend identical with HUVEC.
In addition, because artesunate is water solublity, and metabolite is in vivo dihydroarteannuin, and therefore follow-up animal vivo test adopts artesunate to carry out.
(2) in vivo test
One, experiment purpose
By in vitro tests, analyze artesunate to the impact of retina choroid new vessels.
Two, experimental technique
(1) model of retina in rabbits new vessels is created: rabbit right eye intravitreal 2 μ gVEGF solution 40 μ l.
(2) therapeutic scheme: treat according to following experiment grouping after modeling success:
Model group: intravitreal normal saline 100 μ l;
Artesunate group: obtained by intravitreal artesunate solution 0.1-0.5ml(embodiment 1);
Arastin treatment group: intravitreal 125 μ g/ml Arastin solution 0.15ml(is with reference to quantity);
Normal group: the left eye of all rabbits;
(3) post-operative evaluation index:
Fundus photography, time point: 1 week, 2 weeks, 4 weeks;
Fundus fluorescein angiography, time point: 2 weeks, 4 weeks;
Three, experimental result
Result is see Fig. 3 and Fig. 4.
From Fig. 3 and Fig. 4: retina choroid neovascularization model: through injecting 2 μ g VEGF solution 40 μ l, retina in rabbits vasodilation is tortuous, occur new vessels around optic disc, fluorescein angiography shows new vessels around the obvious seepage of retina choroid and optic disc.
Therapeutic effect is analyzed: the tortuous and retina choroid seepage of untreated model group retina in rabbits vasodilation continues to increase the weight of, 4 weeks afterwards B ultrasonic there is tractional detachment of retina.By intravitreal artesunate injection for treating, retina in rabbits choroidal leekage and new vessels can be obviously suppressed to be formed, the tortuous expansion of retinal vessel obviously alleviates, blood vessel oozes out and around optic disc, new vessels also obviously alleviates, still calm down to treatment 4 weeks rear retinas, have no retina tractive and depart from; After Arastin intravitreal within 2 weeks, have significantly suppress that retina choroid blood vessel oozes out, effect that edema and new vessels are formed, but its injection after 2 weeks effect start to weaken, retina choroid occurs that blood vessel oozes out again, edema and new vessels formation phenomenon.This result shows that artesunate significantly can suppress that retina choroid blood vessel oozes out, edema and new vessels are formed, and the effect that it suppresses that blood vessel oozes out, edema and new vessels are formed comparatively Arastin is more lasting; Due to its persistent, therefore, significantly can reduce the number of times of intraocular injection, decrease the generation of complication.
The above embodiment only have expressed several embodiment of the present invention, and it describes comparatively concrete and detailed, but therefore can not be interpreted as the restriction to the scope of the claims of the present invention.It should be pointed out that for the person of ordinary skill of the art, without departing from the inventive concept of the premise, can also make some distortion and improvement, these all belong to protection scope of the present invention.Therefore, the protection domain of patent of the present invention should be as the criterion with claims.
Claims (10)
1. arteannuin and derivant thereof suppress ocular angiogenesis endothelial cell proliferation in preparation or prevent and treat the application in the medicine of the relevant disease that ocular angiogenesis system is oozed out, edema, new vessels are formed, breed.
2. application according to claim 1, it is characterized in that, described control ocular angiogenesis system is oozed out, edema, new vessels is formed, the relevant disease of propagation is age-related macular degeneration, Diabetic retinopathy, central retinal vein occlusion, branch retinal vein occlusion remaining, retinopathy of prematurity, retinal angiotelectasis disease, macular edema, periphlebitis of retina, polypoidal choroidal vasculopathy in Chinese patients, neovascular glaucoma, cornea rebirth blood vessel, iris neovascularization, choroidal neovascularization, retinal neovascularization, eye and Orbital fat, inflammatory pseudotumor, thyroid-associated ophthalmopathy, thyroid related immune Orbital diseases, features of central exudative chorioretinopathy, the new vessels that high myopia causes and hemorrhage, uveitis, proliferative vitreoretinopathy, traumatic proliferative vitreoretinopathy, retinal angiomatous or meniscocyte's retinal diseases.
3. application according to claim 1, is characterized in that, it is retina choroid neovascular diseases that described new vessels forms relevant disease.
4. the application according to any one of claim 1-3 is characterized in that, described artemisinin derivative is dihydroarteannuin, artesunate, Artemether, arteether or artemisia ketone.
5. one kind for suppressing, ocular angiogenesis endothelial cell proliferation or control ocular angiogenesis system are oozed out, edema, new vessels are formed, the pharmaceutical composition of the relevant disease of propagation, it is characterized in that, the effective ingredient of described pharmaceutical composition is arteannuin and derivant thereof.
6. pharmaceutical composition according to claim 5, is characterized in that, the medicine carrying mode of described pharmaceutical composition is: adopt slow release method that arteannuin and derivant thereof are made nanoparticle, nano-micelle, nanometer microtubule or dendritic macromole; Or arteannuin and derivant thereof to be dissolved on 0.9% sodium chloride solution or medicine in acceptable dissolution solubilizing agent.
7. pharmaceutical composition according to claim 6, it is characterized in that, described dissolution solubilizing agent is: at least one in sodium bicarbonate solution, dimethyl sulfoxide, ethanol, lecithin, lactic acid, glycerol, stearic acid polyethylene, polyvinyl alcohol, soybean phospholipid or poloxamer.
8. pharmaceutical composition according to claim 5, is characterized in that, the dosage form of described pharmaceutical composition is eye drop or injection.
9. pharmaceutical composition according to claim 8, is characterized in that, the route of administration of described injection is: ball is injected outward, implanted treatment or intraocular injection; Described ball is injected as subconjunctival injection, the injection of ball week, retrobulbar injection or sieve plate surrounding injection outward; Described intraocular injection is anterior chamber and intravitreal.
10. the pharmaceutical composition according to any one of claim 5-9, is characterized in that, described artemisinin derivative is dihydroarteannuin, artesunate, Artemether, arteether or artemisia ketone.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410088930.7A CN104906084A (en) | 2014-03-11 | 2014-03-11 | Application of artemisinin and derivatives thereof in preparation of ophthalmic vascular disease prevention and treatment medicines, and medicinal composition |
| PCT/CN2014/085736 WO2015135306A1 (en) | 2014-03-11 | 2014-09-02 | Uses of artemisinin and derivatives thereof in manufacture of medicaments for prevention and treatment of vascular diseases in ophthalmology and pharmaceutical compositions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410088930.7A CN104906084A (en) | 2014-03-11 | 2014-03-11 | Application of artemisinin and derivatives thereof in preparation of ophthalmic vascular disease prevention and treatment medicines, and medicinal composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104906084A true CN104906084A (en) | 2015-09-16 |
Family
ID=54070872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410088930.7A Pending CN104906084A (en) | 2014-03-11 | 2014-03-11 | Application of artemisinin and derivatives thereof in preparation of ophthalmic vascular disease prevention and treatment medicines, and medicinal composition |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN104906084A (en) |
| WO (1) | WO2015135306A1 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107213149A (en) * | 2017-06-07 | 2017-09-29 | 南开大学 | Purposes of the artemisinin derivatives in treatment or auxiliary treatment AITD medicine is prepared |
| CN108354927A (en) * | 2018-03-29 | 2018-08-03 | 上海壹志医药科技有限公司 | The new pharmaceutical uses of arteether |
| CN110025768A (en) * | 2019-06-03 | 2019-07-19 | 上海市第一人民医院 | A kind of construction method of eye disease animal model and its application |
| CN113632765A (en) * | 2021-03-31 | 2021-11-12 | 中山大学中山眼科中心 | Retina neovascular disease animal model, construction method and application thereof |
| WO2022000492A1 (en) * | 2020-07-03 | 2022-01-06 | 中山大学附属第一医院 | Use of artemisinin or derivatives artesunate and dihydroartemisinin |
| CN114106011A (en) * | 2021-10-25 | 2022-03-01 | 中山大学 | Precursor medicine of artemisinin and preparation method and application thereof |
| CN114933603A (en) * | 2022-06-10 | 2022-08-23 | 上海英诺富成生物科技有限公司 | Artemisinin derivative and preparation method and application thereof |
| CN115282145A (en) * | 2022-09-05 | 2022-11-04 | 中南大学湘雅二医院 | Application of artesunate in preparing medicine or preparation for treating glaucoma |
| CN115364091A (en) * | 2022-08-29 | 2022-11-22 | 云白药征武科技(上海)有限公司 | Arteannuin derivative eye preparation and its preparing method |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109874293B (en) * | 2016-08-02 | 2021-11-05 | 斑马药研公司 | Small molecule therapeutic compounds that reduce the incidence of intracerebral hemorrhage and cerebral microhemorrhage |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1699370A (en) * | 2005-06-02 | 2005-11-23 | 桂林制药有限责任公司 | Artesunate salt and its preparation process and use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101427997A (en) * | 2007-11-09 | 2009-05-13 | 中山大学 | Eye drop with anti-cornea rebirth blood vessel function and preparation method thereof |
-
2014
- 2014-03-11 CN CN201410088930.7A patent/CN104906084A/en active Pending
- 2014-09-02 WO PCT/CN2014/085736 patent/WO2015135306A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1699370A (en) * | 2005-06-02 | 2005-11-23 | 桂林制药有限责任公司 | Artesunate salt and its preparation process and use |
Non-Patent Citations (2)
| Title |
|---|
| 刘逸等: "青蒿琥酯对高糖环境下人视网膜微血管内皮细胞增殖及VEGF表达的影响", 《国际眼科杂志》 * |
| 孙京华等: "青蒿琥酯对大鼠角膜新生血管的影响", 《眼外伤职业眼病杂志》 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107213149B (en) * | 2017-06-07 | 2021-03-19 | 南开大学 | Application of artemisinin derivatives in preparation of drugs for treating or assisting in treating autoimmune thyroid diseases |
| CN107213149A (en) * | 2017-06-07 | 2017-09-29 | 南开大学 | Purposes of the artemisinin derivatives in treatment or auxiliary treatment AITD medicine is prepared |
| CN108354927A (en) * | 2018-03-29 | 2018-08-03 | 上海壹志医药科技有限公司 | The new pharmaceutical uses of arteether |
| CN110025768A (en) * | 2019-06-03 | 2019-07-19 | 上海市第一人民医院 | A kind of construction method of eye disease animal model and its application |
| CN110025768B (en) * | 2019-06-03 | 2023-03-21 | 上海市第一人民医院 | Construction method and application of animal model of eye diseases |
| WO2022000492A1 (en) * | 2020-07-03 | 2022-01-06 | 中山大学附属第一医院 | Use of artemisinin or derivatives artesunate and dihydroartemisinin |
| CN113632765B (en) * | 2021-03-31 | 2023-01-03 | 中山大学中山眼科中心 | Retina neovascular disease animal model, construction method and application thereof |
| CN113632765A (en) * | 2021-03-31 | 2021-11-12 | 中山大学中山眼科中心 | Retina neovascular disease animal model, construction method and application thereof |
| CN114106011A (en) * | 2021-10-25 | 2022-03-01 | 中山大学 | Precursor medicine of artemisinin and preparation method and application thereof |
| CN114106011B (en) * | 2021-10-25 | 2023-08-04 | 中山大学 | Prodrug of artemisinin and preparation method and application thereof |
| CN114933603A (en) * | 2022-06-10 | 2022-08-23 | 上海英诺富成生物科技有限公司 | Artemisinin derivative and preparation method and application thereof |
| CN115364091A (en) * | 2022-08-29 | 2022-11-22 | 云白药征武科技(上海)有限公司 | Arteannuin derivative eye preparation and its preparing method |
| CN115282145A (en) * | 2022-09-05 | 2022-11-04 | 中南大学湘雅二医院 | Application of artesunate in preparing medicine or preparation for treating glaucoma |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015135306A1 (en) | 2015-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104906084A (en) | Application of artemisinin and derivatives thereof in preparation of ophthalmic vascular disease prevention and treatment medicines, and medicinal composition | |
| Gupta et al. | Applications of microneedles in delivering drugs for various ocular diseases | |
| Figus et al. | The supraciliary space as a suitable pathway for glaucoma surgery: Ho-hum or home run? | |
| Xue et al. | Genipin-crosslinked donor sclera for posterior scleral contraction/reinforcement to fight progressive myopia | |
| Kusaka | Surgical management of coats disease | |
| RU2368359C1 (en) | Treatment method of age-related macular degeneration | |
| US10278920B1 (en) | Drug delivery implant and a method using the same | |
| US10279046B2 (en) | Eye drop composition for treating ocular inflammatory disease and preparation method therefor | |
| Choe et al. | Subtenon retrobulbar hyaluronidase injection for ophthalmic artery occlusion following facial filler injection | |
| RU2575966C2 (en) | Method of treating neovascular glaucoma | |
| Su et al. | Iatrogenic crystalline lens injury during intravitreal injection of triamcinolone acetonide: A report of two cases | |
| RU2393824C1 (en) | Method of treating macular oedemas of various geneses | |
| Oberg et al. | Topical–intracameral anesthesia without preoperative mydriatic agents for Descemet-stripping automated endothelial keratoplasty and phacoemulsification cataract surgery with intraocular lens implantation | |
| Wang et al. | Accessing the suprachoroidal space for therapeutic delivery | |
| RU2531133C1 (en) | Method of treating secondary glaucoma caused by silicone emulsification | |
| RU2493802C1 (en) | Method of treating retinal detachment | |
| EP1365771B9 (en) | Method of treating certain eye diseases | |
| Pathanapitoon et al. | Choroidal detachment after topical prostaglandin analogs: case report | |
| RU2303457C1 (en) | Method for applying enzymotherapy | |
| Bizrah et al. | EMQs in ophthalmology, dermatology and ENT: an essential revision guide with comprehensive answers | |
| RU2676967C2 (en) | Method of glaucoma surgical treatment | |
| Boboev et al. | Micropulsed transscleral cyclophotocoagulation in the complex treatment of refractory glaucoma.« | |
| RU2698588C1 (en) | Method for simulating filtration pads using scleral-conjunctival dissector | |
| Broadhead et al. | Injections in the back of the eye: The why, the what and when to worry | |
| RU2421195C1 (en) | Method of initial keratoconus treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150916 |
|
| RJ01 | Rejection of invention patent application after publication |